Why Is Caverject So Hard to Find? [Explained for 2026]

If you've been trying to fill a Caverject prescription and running into empty shelves or back-order notices, you're not alone. For years, Caverject — the brand-name injectable form of alprostadil — has been one of the more challenging medications to find at retail pharmacies across the United States. Understanding why it's been scarce, and what has changed in 2025 and 2026, can help you plan your next steps.

What Is Caverject and Who Uses It?

Caverject is a brand name for alprostadil, a prostaglandin E1 (PGE1) drug that is injected directly into the penis to treat erectile dysfunction (ED). It is the only FDA-approved intracavernosal injection therapy for ED and has been on the market since 1981. Caverject is typically prescribed for men who do not respond adequately to oral ED medications like sildenafil (Viagra) or tadalafil (Cialis), as well as for men recovering from prostate surgery.

In clinical studies, over 80% of patients who used Caverject experienced an erection sufficient for sexual intercourse. The medication produces an erection within 5 to 20 minutes and lasts up to 60 minutes on average, making it a highly effective option for men with severe or medication-resistant ED.

Why Has Caverject Been So Hard to Find?

The difficulty finding Caverject stems from several overlapping factors:

1. The 2023 Manufacturing Shortage

In 2023, Pfizer issued a formal supply alert notifying healthcare providers and pharmacies that Caverject Dual Chamber would be in stock-out, with an estimated recovery timeline of mid-2024. The 40 mcg vials faced a similar disruption starting around June 2023. The cause was unusual: an unforeseen shortage of a hormone deficiency medicine made by a competitor led to an unprecedented surge in demand for a different Pfizer drug — one that used the same manufacturing capacity. This forced Pfizer to deprioritize Caverject production.

For patients who depended on Caverject, this was an especially frustrating shortage — the medication is not interchangeable with oral ED drugs, and there was no easy substitute.

2. Pfizer Discontinued the Caverject Brand in 2025

In July 2025, Pfizer announced the discontinuation of several branded products, including Caverject, and released generic equivalents of alprostadil in their place. This transition from brand to generic created another period of pharmacy uncertainty — some pharmacies had depleted their Caverject brand stock but had not yet stocked the new generic alprostadil vials.

For patients with prescriptions written specifically for "Caverject," this could cause confusion at the pharmacy counter. If your pharmacy says Caverject is unavailable, ask specifically whether they carry generic alprostadil injection at the same dosage strength.

3. Limited Number of Pharmacies Stocking Injectable ED Medications

Even during periods of adequate national supply, Caverject and alprostadil injections are considered specialty medications. Not every pharmacy keeps them on hand. Many large chain pharmacies — Walgreens, CVS, Rite Aid — may not stock alprostadil at all locations, and independent pharmacies that specialize in compounding or urology medications are often a better source.

4. Competing Demand and Compounded Alternatives

Many men who need injectable ED therapy switch to compounded Trimix — a combination of alprostadil, papaverine, and phentolamine — because it is often less expensive and produces less pain than alprostadil alone. Compounding pharmacies produce Trimix to order and may have more flexible supply chains than commercial manufacturers. However, Trimix is not FDA-approved as a specific product and must be prepared by licensed compounding pharmacies.

Is Caverject Available in 2026?

The good news for 2026 is that generic alprostadil injection is now on the market following Pfizer's brand discontinuation. New manufacturers have entered the space — Meitheal Pharmaceuticals launched an alprostadil injection product in March 2025. Caverject Impulse (the pre-filled syringe version) may still be found at some pharmacies as remaining brand stock is worked through.

That said, availability is still inconsistent. Alprostadil injection remains a niche product that not all pharmacies stock routinely. Your best strategy is to call ahead — or use a service like medfinder to check which pharmacies in your area can fill your prescription.

What Can You Do If Your Pharmacy Doesn't Have It?

Ask your pharmacy if generic alprostadil injection is available as a substitute for Caverject.

Contact a compounding pharmacy to ask about Trimix or compounded alprostadil.

Ask your urologist or prescriber if Edex (another brand of alprostadil injection) is an option.

Use medfinder to locate pharmacies near you that can fill your prescription — saving you from calling dozens of pharmacies yourself.

How medfinder Can Help

Finding alprostadil injection doesn't have to mean spending hours on hold with pharmacies. medfinder is a service that calls pharmacies on your behalf to find out which ones have your medication in stock. You provide your medication, dose, and zip code — medfinder does the calling and texts you the results. It works for Caverject, generic alprostadil injection, and other injectable ED medications.

For more strategies, see our guide on how to find Caverject in stock near you.

The Bottom Line

Caverject's availability challenges in 2026 are a product of multiple factors: a major 2023 manufacturing disruption, Pfizer's brand discontinuation in 2025, and the inherently limited pharmacy stocking of specialty injectable medications. While generic alprostadil is now entering the market, inconsistent pharmacy coverage means patients still need to shop around. The good news is that there are more tools than ever to help you find it — and more alternatives available if the exact formulation you need isn't in stock.